Barclays raised the firm’s price target on Exelixis to $25 from $24 and keeps an Overweight rating on the shares. The CONTACT-02 data was encouraging and could support FDA approval, pending more mature survival data, the analyst tells investors in a research note. The firm updated its model to reflect initial assumptions for cabozantinib in metastatic castration-resistant prostate cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EXEL:
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Exelixis announces results of study evaluating cabozantinib in mCRPC treatment
- Bristol Myers, Exelixis announce four-year results from Opdivo-Cabometyx trial
- EPO rules in favor of Exelixis on patent covering Cabometyx
- Biotech Alert: Searches spiking for these stocks today
